Study links canine and human mortality biomarkers: full analysis

Dogs may be even more useful to aging science than many clinicians already assume. A new study from the Dog Aging Project found that blood metabolites linked to mortality in humans track closely with mortality-associated metabolites in dogs, suggesting that the biology underlying aging and lifespan risk is conserved across the two species. The paper, published online on December 22, 2025, and appearing in the April 2026 issue of The Journals of Gerontology: Series A, frames companion dogs as a faster, real-world model for studying aging biology. (academic.oup.com)

That conclusion builds on years of work positioning dogs as a translational aging model. The Dog Aging Project launched in 2019 as a joint effort between Texas A&M and the University of Washington, with the goal of studying how genetics, environment, and lifestyle shape healthy aging in companion dogs. Unlike laboratory models, pet dogs share human-built environments, receive routine veterinary care, and develop many of the same age-related diseases as people, but on a compressed lifespan. Researchers have argued for years that this makes dogs especially valuable for geroscience, and the project has now enrolled more than 50,000 U.S. dogs. (vetmed.tamu.edu)

In the new study, investigators used longitudinal survival models on plasma metabolomics data from 937 dogs in the Dog Aging Project’s Precision Cohort. They measured 133 metabolites and found that about 17% were associated with all-cause mortality, with 23 reaching statistical significance after false-discovery adjustment. The team then compared those canine signals with results from five independent human metabolomics studies and found a 64% concordance in the direction of mortality risk for shared metabolites, with a highly significant p-value. The authors said that overlap points to a general mortality signature in the plasma metabolome that appears in both humans and dogs. (academic.oup.com)

The broader Dog Aging Project infrastructure helps explain why the field is paying attention. The Precision Cohort includes annual follow-up with blood collection and other deep phenotyping, while the larger project captures survey, clinical, genomic, microbiome, epigenome, and laboratory data. Researchers say that setup allows them to identify mortality-linked biomarkers in a timeframe far shorter than comparable human cohorts, which often require many years or decades of follow-up. Daniel Promislow, a Dog Aging Project leader, has previously said that because dogs “live in our environment” but age faster, researchers can learn much more quickly from them than from human cohorts alone. (academic.oup.com)

Industry and academic reaction is likely to center less on novelty and more on validation. The main message is not simply that dogs and humans age in parallel, but that measurable blood-based mortality signals may be conserved enough to support intervention research. That matters because the Dog Aging Project is already moving beyond observation. In December 2024, Texas A&M announced a $7 million NIH grant to expand TRIAD, its multicenter rapamycin trial in middle-aged dogs, with plans to grow enrollment from 170 dogs to 580. Prior Dog Aging Project work has also examined metabolomic and other molecular signatures of aging, including age-related shifts in lipid metabolism and broader biomarker discovery efforts. (vetmed.tamu.edu)

Why it matters: For veterinary professionals, this is a reminder that companion-animal practice is increasingly connected to translational biomedicine. If canine metabolomic markers continue to prove predictive, they could eventually inform how veterinarians think about aging risk, preventive monitoring, and enrollment in clinical studies for older dogs. Just as important, the research reinforces the value of primary care practices and pet parent participation in generating usable aging data, since community veterinarians are central to sample collection and follow-up in the Dog Aging Project model. That said, this is still research-stage work: the study supports biological similarity and biomarker discovery, but it does not yet create a clinically validated test for individual canine patients. (academic.oup.com)

What to watch: The next milestones are likely to be disease-specific prediction studies, validation of biomarker panels in additional cohorts, and readouts from intervention programs such as TRIAD. The authors also say continued follow-up of enrolled dogs could reveal predictive markers from other data layers, including epigenomic, microbiome, and clinical pathology datasets, giving veterinary medicine a larger role in how aging interventions are developed and assessed. (academic.oup.com)